This phase I/II study is evaluating the safety, recommended dose level, and effectiveness of a new treatment (WU-CART-007) in people with relapsed or refractory T-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma.
This trial is treating patients with relapsed or refractory T-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Commercial Sponsor
Wugen, Inc.
Summary
This study consists of two phases. In Phase 1 (Dose Escalation), up to 24 participants will be treated with 2 dose of WU-CART-007, in up to 4 dose levels, until the maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined. Once the recommended phase 2 dose (RP2D) is defined, the Phase 2 portion (Cohort Expansion) will enrol expansion cohorts. WU-CART-007 will be administered via single intravenous (IV) infusion on Day 1 after Lymphodepletion (LD) Therapy. Cyclophosphamide 500mg/m2/day x 3 (days -5 to -3) Fludarabine 30mg/m2/day x 3 (days -5 to -3).
Recruiting Hospitals Read More